Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,029 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.
Pressiat C, Hirt D, Treluyer JM, Zheng Y, Morlat P, Naqvi A, Tran L, Viard JP, Avettand-Fenoel V, Rouzioux C, Meyer L, Cheret A; OPTIPRIM Study Group. Pressiat C, et al. Among authors: tran l. J Antimicrob Chemother. 2018 Apr 1;73(4):1020-1024. doi: 10.1093/jac/dkx498. J Antimicrob Chemother. 2018. PMID: 29365125 Clinical Trial.
HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.
Frange P, Assoumou L, Descamps D, Chéret A, Goujard C, Tran L, Gousset M, Avettand-Fenoël V, Bocket L, Fafi-Kremer S, Guinard J, Morand-Joubert L, Nicot F, Plantier JC, Rogez S, Wirden M, Rouzioux C, Meyer L, Chaix ML; French ANRS CO 6 PRIMO Cohort, the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups; French ANRS CO 6 PRIMO Cohort the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups. Frange P, et al. Among authors: tran l. J Antimicrob Chemother. 2015 Jul;70(7):2084-9. doi: 10.1093/jac/dkv049. Epub 2015 Feb 26. J Antimicrob Chemother. 2015. PMID: 25885327
No evidence of a change in HIV-1 virulence since 1996 in France.
Troude P, Chaix ML, Tran L, Deveau C, Seng R, Delfraissy JF, Rouzioux C, Goujard C, Meyer L; ANRS Primo cohort. Troude P, et al. Among authors: tran l. AIDS. 2009 Jun 19;23(10):1261-7. doi: 10.1097/QAD.0b013e32832b51ef. AIDS. 2009. PMID: 19424055
Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy.
Chaix ML, Seng R, Frange P, Tran L, Avettand-Fenoël V, Ghosn J, Reynes J, Yazdanpanah Y, Raffi F, Goujard C, Rouzioux C, Meyer L; ANRS PRIMO Cohort Study Group. Chaix ML, et al. Among authors: tran l. Clin Infect Dis. 2013 Mar;56(6):880-7. doi: 10.1093/cid/cis999. Epub 2012 Dec 7. Clin Infect Dis. 2013. PMID: 23223603
Factors Associated With Being Overweight and Obesity in People Living With Human Immunodeficiency Virus on Antiretroviral Therapy: Socioclinical, Inflammation, and Metabolic Markers.
Goupil de Bouillé J, Vigouroux C, Plessis L, Ghislain M, Teglas JP, Boufassa F, Goujard C, Vignes D, Bouchaud O, Salmon D, Meyer L, Abgrall S; ANRS CO9-COPANA study group. Goupil de Bouillé J, et al. J Infect Dis. 2021 Nov 16;224(9):1570-1580. doi: 10.1093/infdis/jiab151. J Infect Dis. 2021. PMID: 33740044
2,029 results